Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to -$2.0 million.

  • Pliant Therapeutics' Change in Accured Expenses fell 13929.95% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.8 million, marking a year-over-year decrease of 25780.52%. This contributed to the annual value of $3.8 million for FY2024, which is 3689.32% up from last year.
  • Pliant Therapeutics' Change in Accured Expenses amounted to -$2.0 million in Q3 2025, which was down 13929.95% from -$3.8 million recorded in Q2 2025.
  • Pliant Therapeutics' Change in Accured Expenses' 5-year high stood at $5.8 million during Q2 2022, with a 5-year trough of -$6.1 million in Q4 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$364000.0 (2022), whereas its average is $343894.7.
  • In the last 5 years, Pliant Therapeutics' Change in Accured Expenses surged by 987142.86% in 2021 and then tumbled by 97668.1% in 2024.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Change in Accured Expenses stood at $2.0 million in 2021, then crashed by 120.8% to -$411000.0 in 2022, then skyrocketed by 270.07% to $699000.0 in 2023, then plummeted by 976.68% to -$6.1 million in 2024, then surged by 66.86% to -$2.0 million in 2025.
  • Its Change in Accured Expenses stands at -$2.0 million for Q3 2025, versus -$3.8 million for Q2 2025 and -$4.8 million for Q1 2025.